Abstract
Semaglutide is a gluten-like peptide 1 (GLP-1) agonist which is responsible for improving blood sugar control and losing weight. It is clinically approved by the FDA for treatment of type 2 diabetes mellitus and is designed in subcutaneous or oral dosage form. Some other diseases share common conditions with obesity and diabetes such as a high blood sugar level and insulin resistance. These factors along with some neuron issues are responsible for neurodegenerative diseases. Obesity and diabetes are two common worldwide health issues. A number of trials have been conducted to estimate the prevalence and drug effects. Scientists also study related diseases such as Non-alcoholic fatty liver disease to verify the usefulness of treatments. Semaglutide is one of the drugs being measured whether has a potential effect on these diseases. Some pre-clinical studies have indicated its therapeutic potential in non-alcoholic steatohepatitis and neurodegenerative disorders. Semaglutide has proved to be effective in treating lots of disorders, especially diabetes and obesity. However, for other diseases, it still remains uncertain even if there are some studies already tested the effectiveness. Much more detailed and considerate studies should be conducted to verify the impact. Semaglutide, the GLP-1 receptor agonist, has shown a positive impact in treating different diseases. Researchers have tested hepatoprotective and neuroprotective activity in animal and human trials to get more reliable data. It turns out that semaglutide improves insulin resistance and reduces blood sugar levels. It also protects dopaminergic neurons and reduces aggregated α-synuclein which improves Parkinson’s disease and Alzheimer’s disease conditions.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call